Background
Cryptococcal lateral flow antigen assays (CLFAs) have been assessed in comparison to the latex cryptococcal antigen agglutination test but their clinical performance is unknown.
Objective
Determine clinical performance of IMMY CLFA (Immuno‐Mycologics Inc, Oklahoma) using patients with and without cryptococcosis as the reference standard.
Animals
One‐hundred ninety‐seven serum samples from client‐owned dogs and cats.
Methods
Review of medical records of a referral population of dogs and cats that had CLFA performed between 2012 and 2020. Animals were classified as cryptococcosis positive (Cr+) or negative (Cr−) based on clinical information. Clinical diagnosis was used to calculate positive and negative percent agreement of the CLFA.
Results
Twelve specimens (4 canine, 8 feline) were obtained from Cr+ animals and had positive CLFA results. One‐hundred eighty‐five specimens (139 canine, 46 feline) were collected from Cr− animals. Negative CLFA results were recorded in 129 canine and 44 feline Cr− samples. Positive CLFA results were noted for 10 canine and 2 feline Cr− samples. Positive percent agreement of CLFA was 100% (confidence interval [CI], 39.8%‐100% dogs; 63.1%‐100% cats). Negative percent agreements were 92.8% (CI, 87.2%‐96.5%) for dogs and 95.7% (CI, 85.2%‐99.5%) for cats.
Conclusions and Clinical Importance
A negative IMMY CLFA result enables reliable exclusion of cryptococcal infection in dogs and cats. By contrast, a positive result must be interpreted cautiously and further testing should be performed to verify a diagnosis of cryptococcosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.